Annals of Oncology 14:6-7, 2003
© 2003 European Society for Medical Oncology
Editorial |
Pegfilgrastim: the promise of pegylation fulfilled
Division of Medical Oncology and Transplantation, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA
| The first 10% of the full text of this article appears below. |
The laboratory and clinical investigation of hematopoietic growth factors has had a profound impact on the practice of oncology and the care of cancer patients [1]. In studies with these agents, we have learnt not only about the biological effects these agents have on the hematopoietic system, but also about the clinical benefit that occurs by reducing treatment-related anemia, neutropenia and thrombocytopenia. With regard to the colony-stimulating factors (G-CSF, GM-CSF) our knowledge base continues to grow and guidelines for clinical use continue to undergo revision [2]. In addition to reducing the toxicity of myelosuppressive chemotherapy for millions of cancer patients, these agents have also been integral to the study of chemotherapy dose intensity and dose density. The science of stem cells has been heavily dependent on the study of the hematopoietic cytokines and their regulation and interaction. As a